October 27, 2017 09:26 AM EDT
R&D
Pharma

Brush­ing back biosims, a con­fi­dent Ab­b­Vie out­lines a block­buster win­ning streak ahead for Hu­mi­ra

John Carroll

Editor & Founder

While Gilead and Cel­gene were show­ing just how sig­nif­i­cant new pric­ing com­pe­ti­tion can be in de­stroy­ing their fore­cast­ing abil­i­ties, Ab­b­Vie showed up Fri­day morn­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

A service from the Financial Times